/

VTGN

VistaGen Therapeutics, Inc.Closed

0.2148−0.01 −5.21%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.2200 +2.42%

Open

0.2233

Prev close

0.2266

Day range

0.21240.2250

52-week range

0.20005.14

Volume

1.03M0.08×

Mkt cap

9.53M

P/E ttm

—

Fwd P/E

-0.14

EPS ttm

-1.66

Div yield

0.00%

Earnings

Aug 14, 2026

From 52w high

−95.82%

Price Chart

Yahoo Finance · delayed

VTGNOct 13, 2026O 0.2200H 0.2300L 0.2100C 0.2100−0.0200 (−8.70%)Vol 1.03M

SMA 500.2588
SMA 2000.4786

1Y change −94.63% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VTGN VistaGen Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −16.00%
1 month: −12.50%
3 months: −16.00%
6 months: −65.00%
Year to date: −68.18%
1 year: −94.63%

Valuation & ownership

Market cap: 9.53M
Enterprise value: −21.41M
P/E (ttm): —
Forward P/E: -0.14
PEG ratio: —
Price / book: 0.39
Price / sales (ttm): 3.81
EV / EBITDA: 0.31
EPS (ttm): -1.66
EPS (forward): -1.54
Beta (5y monthly): 0.33
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 44.38M
Float: 41.42M
Short % of float: 8.48%
Short ratio (days): 0.13
Held by insiders: 0.37%
Held by institutions: 31.05%
Avg volume (3m): 12.50M
50-day average: 0.2596
200-day average: 0.4812
52-week change: −94.63%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 37.6
vs 50-day SMA: −18.86%
vs 200-day SMA: −56.12%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 14.32%
Realised vol (20d, ann.): 186.3%
From 52-week high: −95.91%
From 52-week low: +5.00%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

1.00

+365.55% implied

Low 1.00Median 1.00High 1.00

Recommendation trend

Now0 / 4 / 0
1m ago0 / 4 / 0

Buy / hold / sell counts

DES

About VistaGen Therapeutics, Inc.

Yahoo Finance profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 41
Headquarters: South San Francisco, CA, United States
Website: vistagen.com
Officers

SEAS

Seasonality · VTGN

2011–2026 · monthly returns

Strongest month Aug +18.25%Weakest month Feb −10.93%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-15.2	5.4	-3.4	7.0	3.3	-63.5	4.3	8.3	19.2	-30.7			−67.5%
2025	-2.0	-6.6	-7.4	-6.4	10.3	-22.5	43.5	16.4	6.3	11.0	24.4	-86.5	−77.6%
2024	-7.0	6.9	3.3	-8.5	-20.1	-9.8	-1.4	1.7	-13.8	2.3	-7.8	3.9	−42.6%
2023	160.0	-30.8	-33.3	16.7	0.0	-55.5	-2.7	192.9	-1.7	-39.3	12.9	43.2	+71.3%
2022	-16.4	-14.1	-11.4	2.4	-9.4	-23.5	-84.1	28.6	-16.7	-13.3	7.7	-28.6	−94.9%
2021	9.3	16.5	-13.8	18.8	2.4	21.6	-15.6	14.3	-9.9	-16.4	-15.7	1.0	+0.5%
2020	7.2	-31.1	-13.7	0.0	0.0	20.5	75.5	-24.7	0.0	2.9	5.6	155.3	+181.2%
2019	10.0	-31.5	13.3	-16.4	-20.6	-14.1	-30.1	33.3	57.4	5.6	-57.5	43.8	−54.0%
2018	10.8	-1.6	-23.1	7.5	41.0	-2.8	-8.0	16.7	-1.4	39.3	-10.9	-16.7	+35.1%
2017	-19.8	-14.7	-23.1	1.0	-4.5	-1.1	9.6	-14.1	-9.1	-47.5	-8.3	44.2	−70.2%
2016	-13.6	-5.9	9.4	-2.9	-55.3	2.6	-15.1	3.9	23.0	-6.6	-7.1	1.6	−62.1%
2015	-5.9	0.0	25.0	-19.0	23.5	50.0	-25.0	-8.4	-2.9	-25.1	-11.2	48.0	+15.8%
2014	9.5	-15.2	17.9	4.3	31.3	1.6	-4.7	14.8	-25.0	-9.5	10.5	-19.0	+1.2%
2013	9.6	-20.0	29.7	6.0	-9.1	-25.0	1.7	-1.6	1.7	-39.3	-16.2	35.5	−42.5%
2012	-1.6	-5.0	-3.9	-26.6	-74.6	33.3	25.0	10.6	-14.9	18.8	-27.4	5.8	−76.1%
2011							-3.8	-10.4	15.6	13.9	-1.7	5.2	+17.3%

INSD

Insider Activity · VTGN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 29, 2026	Singh Shawn KChief Executive Officer	Stock Award(Grant) at price 0.19 per share.	36.8K	$7.07K
Jun 29, 2026	Tressler Nick BChief Financial Officer	Stock Award(Grant) at price 0.19 per share.	11.7K	$2.25K
Jun 29, 2026	Adler Reid G.Officer	Stock Award(Grant) at price 0.19 per share.	36.8K	$7.07K
Dec 30, 2025	Prince Joshua SChief Operating Officer	Stock Award(Grant) at price 0.56 per share.	4.4K	$2.47K
Jun 29, 2025	Singh Shawn KChief Executive Officer	Stock Award(Grant) at price 1.70 per share.	7.5K	$12.82K
Jun 29, 2025	Adler Reid G.Officer	Stock Award(Grant) at price 1.70 per share.	7.5K	$12.82K
Jun 29, 2025	Anderson Cynthia LynnChief Financial Officer	Stock Award(Grant) at price 1.70 per share.	6.6K	$11.25K
Jun 29, 2025	Prince Joshua SChief Operating Officer	Stock Award(Grant) at price 1.70 per share.	4.9K	$8.30K
Dec 30, 2024	Anderson Cynthia LynnChief Financial Officer	Stock Award(Grant) at price 2.51 per share.	2.6K	$6.50K
Dec 30, 2024	Prince Joshua SChief Operating Officer	Stock Award(Grant) at price 2.51 per share.	3.3K	$8.30K

13F

Investors Holding VTGN

latest 13F filings of 29 followed managers

Investors holding VTGN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$165.1K	0.00%	730.50K	+151%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

VTGN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VTGN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About VistaGen Therapeutics, Inc.

Seasonality · VTGN

Insider Activity · VTGN

Congress Trades · VTGN

Investors Holding VTGN

Investors Holding VTGN

Congress Trades · VTGN

Insider Activity · VTGN

Seasonality · VTGN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About VistaGen Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News